Literature DB >> 14991118

[Indinavir urolithiasis in HIV-positive patients. Treatment and prophylaxis].

C Kalaitzis1, S Touloupidis, E Patris, K Lehrich, R M Kuntz.   

Abstract

TARGET: The approximate incidence of indinavir urolithiasis in HIV positive patients receiving the drug is 10%. The exact mechanism of lithogenesis is still unknown. Pure indinavir stones are radiolucent on plane abdominal X-ray or CT scan. Indinavir urolithiasis can be associated with acute unilateral renal colic or severe azotaemia.
MATERIAL AND METHODS: 20 HIV patients were treated conservatively by increasing oral fluid intake (urine production of 2 l/day and more), discontinuation of indinavir therapy for 1 week and acidification of urine with l-methionin (urine pH 5,3-5,8). Some patients were additionally treated with endoscopic procedures.
RESULTS: In all patients renal function normalized. Increase of oral fluid intake, especially during the first 2 hours after intake of indinavir and during night prevented recurrence of indinavir urolithiasis.
CONCLUSION: HIV positive patients with renal colic or renal insufficiency and roentgenological absence of radio-opaque stone formations should make the urologist consider indinavir urolithiasis as a possible diagnosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14991118     DOI: 10.1007/s00120-003-0492-3

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  10 in total

1.  Is indinavir crystalluria an indicator for indinavir stone formation?

Authors:  S Salahuddin; Y S Hsu; N P Buchholz; J P Dieleman; I C Gyssens; D J Kok
Journal:  AIDS       Date:  2001-05-25       Impact factor: 4.177

2.  HIV/AIDS case histories: indinavir crystalluria.

Authors:  T A Godwin
Journal:  AIDS Patient Care STDS       Date:  2001-03       Impact factor: 5.078

3.  Indinavir nephropathy.

Authors:  K T Tashima; J D Horowitz; S Rosen
Journal:  N Engl J Med       Date:  1997-01-09       Impact factor: 91.245

Review 4.  Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir.

Authors:  R M Hoetelmans; P L Meenhorst; J W Mulder; D M Burger; C H Koks; J H Beijnen
Journal:  Pharm World Sci       Date:  1997-08

5.  Urinary stones in HIV-1-positive patients treated with indinavir.

Authors:  M Daudon; L Estépa; J P Viard; D Joly; P Jungers
Journal:  Lancet       Date:  1997-05-03       Impact factor: 79.321

6.  Indinavir nephropathy revisited: a pattern of insidious renal failure with identifiable risk factors.

Authors:  R F Reilly; K Tray; M A Perazella
Journal:  Am J Kidney Dis       Date:  2001-10       Impact factor: 8.860

7.  Protease inhibitor-induced urolithiasis.

Authors:  D L Gentle; M L Stoller; T W Jarrett; J F Ward; K S Geib; A F Wood
Journal:  Urology       Date:  1997-10       Impact factor: 2.649

8.  Urolithiasis associated with the protease inhibitor indinavir.

Authors:  R G Bruce; L C Munch; A D Hoven; R S Jerauld; R Greenburg; W H Porter; P W Rutter
Journal:  Urology       Date:  1997-10       Impact factor: 2.649

9.  L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor.

Authors:  J P Vacca; B D Dorsey; W A Schleif; R B Levin; S L McDaniel; P L Darke; J Zugay; J C Quintero; O M Blahy; E Roth
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

10.  New drugs for HIV infection.

Authors: 
Journal:  Med Lett Drugs Ther       Date:  1996-04-12       Impact factor: 1.909

  10 in total
  2 in total

1.  Urological management of indinavir-associated acute renal failure in HIV-positive patients.

Authors:  C Kalaitzis; P Passadakis; S Giannakopoulos; S Panagoutsos; E Mpantis; A Triantafyllidis; S Touloupidis; V Vargemezis
Journal:  Int Urol Nephrol       Date:  2006-12-19       Impact factor: 2.370

Review 2.  [History of epidemics in urology in German-speaking countries].

Authors:  F H Moll; T Halling; M Griemmert
Journal:  Urologe A       Date:  2020-08       Impact factor: 0.803

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.